175 related articles for article (PubMed ID: 37242487)
1. Diosgenin and Monohydroxy Spirostanol from
Shalayel MHF; Al-Mazaideh GM; Alanezi AA; Almuqati AF; Alotaibi M
Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242487
[TBL] [Abstract][Full Text] [Related]
2. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach.
Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK
Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395
[TBL] [Abstract][Full Text] [Related]
3. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
4. Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
Bello M; Saldaña-Rivero L; Correa-Basurto J; García B; Sánchez-Espinosa VA
Int J Biol Macromol; 2018 May; 111():569-586. PubMed ID: 29329808
[TBL] [Abstract][Full Text] [Related]
5. Molecular recognition of tak-285 and lapatinib by inactive, active, and middle active-inactive HER2.
Martiniano B
J Mol Model; 2021 Mar; 27(4):105. PubMed ID: 33686576
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic inhibition of gastric cancer-associated bacteria
Akash S; Bayıl I; Mahmood S; Mukerjee N; Mili TA; Dhama K; Rahman MA; Maitra S; Mohany M; Al-Rejaie SS; Ali N; Semwal P; Sharma R
Heliyon; 2023 Oct; 9(10):e20670. PubMed ID: 37876433
[TBL] [Abstract][Full Text] [Related]
7. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
9. Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model.
Nakayama A; Takagi S; Yusa T; Yaguchi M; Hayashi A; Tamura T; Kawakita Y; Ishikawa T; Ohta Y
J Cancer; 2013; 4(7):557-65. PubMed ID: 23983820
[TBL] [Abstract][Full Text] [Related]
10. Identification of phytocompounds as potent inhibitors of sodium/glucose cotransporter-2 leading to diabetes treatment.
Swargiary A; Daimari M; Swargiary A; Biswas A; Brahma D; Singha H
J Biomol Struct Dyn; 2024 Feb; ():1-14. PubMed ID: 38379332
[TBL] [Abstract][Full Text] [Related]
11. Screening of phytochemicals as potential anti-breast cancer agents targeting HER2: an in-silico approach.
Lamichhane S; Rai RP; Khatri A; Adhikari R; Shrestha BG; Shrestha SK
J Biomol Struct Dyn; 2023 Feb; 41(3):897-911. PubMed ID: 34957911
[TBL] [Abstract][Full Text] [Related]
12.
Rolta R; Yadav R; Salaria D; Trivedi S; Imran M; Sourirajan A; Baumler DJ; Dev K
J Biomol Struct Dyn; 2021 Nov; 39(18):7017-7034. PubMed ID: 32851912
[TBL] [Abstract][Full Text] [Related]
13. Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2.
Balbuena-Rebolledo I; Padilla-Martínez II; Rosales-Hernández MC; Bello M
Pharmaceuticals (Basel); 2021 Aug; 14(8):. PubMed ID: 34451888
[TBL] [Abstract][Full Text] [Related]
14. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, Biological Evaluation, and Molecular Dynamics Studies of Novel Lapatinib Derivatives.
Elkamhawy A; Son S; Lee HY; El-Maghrabey MH; Hamd MAE; Alshammari SO; Abdelhameed AA; Alshammari QA; Abdeen A; Ibrahim SF; Mahdi WA; Alshehri S; Alnajjar R; Choi WJ; Al-Karmalawy AA; Lee K
Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678540
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG
Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639
[TBL] [Abstract][Full Text] [Related]
17. Dissecting the molecular recognition of dual lapatinib derivatives for EGFR/HER2.
Bello M; Guadarrama-García C; Rodriguez-Fonseca RA
J Comput Aided Mol Des; 2020 Mar; 34(3):293-303. PubMed ID: 31828486
[TBL] [Abstract][Full Text] [Related]
18. Reckoning apigenin and kaempferol as a potential multi-targeted inhibitor of EGFR/HER2-MEK pathway of metastatic colorectal cancer identified using rigorous computational workflow.
Sharma A; Sinha S; Rathaur P; Vora J; Jha PC; Johar K; Rawal RM; Shrivastava N
Mol Divers; 2022 Dec; 26(6):3337-3356. PubMed ID: 35147860
[TBL] [Abstract][Full Text] [Related]
19. Molecular docking and dynamic simulation to identify potential phytocompound inhibitors for EGFR and HER2 as anti-breast cancer agents.
Prabhavathi H; Dasegowda KR; Renukananda KH; Karunakar P; Lingaraju K; Raja Naika H
J Biomol Struct Dyn; 2022 Jul; 40(10):4713-4724. PubMed ID: 33345701
[TBL] [Abstract][Full Text] [Related]
20. In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2.
Ahmed M; Sadek MM; Abouzid KA; Wang F
J Mol Graph Model; 2013 Jul; 44():220-31. PubMed ID: 23911931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]